Karyopharm Therapeutics Inc.
KPTI
$7.46
$1.1518.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -11.35% | -9.39% | -9.50% | 7.70% | 13.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -11.35% | -9.39% | -9.50% | 7.70% | 13.86% |
| Cost of Revenue | -15.05% | -3.80% | -10.95% | 2.66% | 21.93% |
| Gross Profit | 38.64% | -40.24% | 5.71% | 396.48% | -39.89% |
| SG&A Expenses | -8.35% | -7.44% | -11.40% | -10.30% | -9.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.11% | -5.40% | -13.60% | -3.27% | 5.59% |
| Operating Income | 13.28% | 1.49% | 17.26% | 15.92% | 4.91% |
| Income Before Tax | -255.97% | 37.18% | 25.94% | 7.10% | 173.41% |
| Income Tax Expenses | -40.30% | -49.30% | -183.85% | 133.33% | -47.24% |
| Earnings from Continuing Operations | -256.57% | 37.20% | 26.43% | 7.05% | 172.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -256.57% | 37.20% | 26.43% | 7.05% | 172.91% |
| EBIT | 13.28% | 1.49% | 17.26% | 15.92% | 4.91% |
| EBITDA | 13.27% | 1.47% | 17.31% | 15.97% | 4.95% |
| EPS Basic | -291.06% | 32.98% | 32.92% | 14.94% | 152.78% |
| Normalized Basic EPS | -67.13% | 42.90% | 32.47% | 14.99% | 39.49% |
| EPS Diluted | -45.40% | 32.98% | 32.37% | 13.80% | 31.67% |
| Normalized Diluted EPS | -113.22% | 42.90% | 32.47% | 14.99% | 52.57% |
| Average Basic Shares Outstanding | 6.83% | 10.01% | 9.67% | 9.27% | 5.98% |
| Average Diluted Shares Outstanding | -16.27% | 10.01% | 9.67% | 9.27% | 35.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |